Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Guselkumab Not Linked to Worsening Liver Fibrosis in Psoriasis, 3-Year Study Finds

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

SYSA1902 Clinically Equivalent to Ustekinumab for Plaque Psoriasis

Test your knowledge below on pooled data from the ADORING trial program and stay up to date with clinical advancements in atopic dermatitis.

Clinical Quiz: ADORING Trial and Tapinarof Cream for Atopic Dermatitis

The interchangeable designation was granted to CT-P17, a biosimilar to adalimumab (Humira), for inflammatory diseases such as psoriasis. 

FDA Grants Interchangeable Designation to Adalimumab Biosimilar CT-P17 (Yuflyma)

This segment of the latest interview with Lawrence Eichenfield, MD, features a discussion about the ICONIC-LEAD study.

Significance of Icotrokinra Findings for Adolescents with Psoriasis, with Lawrence Eichenfield, MD

An audio recap of the top 5 stories in healthcare news from the week of 03/31-04/06.



HCPLive 5 Stories in Under 5: Week of 04/06

In this interview, Lawrence Eichenfield, MD, speaks on his team’s recent research on icotrokinra for patients with moderate-to-severe plaque psoriasis. 

Notable Attributes of Icotrokinra for Adolescents with Psoriasis, with Lawrence Eichenfield, MD

Our top 5 headlines spotlight developments in AI-driven care, diabetes tech, and dermatology, alongside key FDA actions in ophthalmology and nephrology.

The HCPFive: Top News for Healthcare Providers from the Week of 04/06

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

Icotrokinra Clears Skin Among 75% of Adolescents with Plaque Psoriasis

In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.

Q1 2025 Recap: Dermatology News and Updates

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.